Profitability & MarginsConsistently high gross and operating margins indicate durable cost advantages and efficient operations. Such margins provide a buffer through development cycles, support sustained R&D and clinical programs, and increase the firm's ability to reinvest in long‑term product development without eroding profitability.

Balance Sheet StrengthA low debt-to-equity ratio and solid equity ratio point to structural financial stability, lowering refinancing and interest risks. This balance sheet flexibility supports multi‑period R&D spending and strategic investments, making the company less vulnerable to funding shocks over the next several quarters.

Operating Cash ConversionOperating cash converts profit into cash at better-than-one-to-one rates, showing core business cash generation discipline. Strong cash conversion supports ongoing operations and capital deployment choices, and indicates underlying earnings quality that can sustain growth initiatives over a multi‑quarter horizon.

Bears Say

Negative Free Cash FlowA turn to negative free cash flow signals that capital expenditures or working capital needs outpace operating cash, reducing financial flexibility. Over several quarters this can constrain funding for trials, manufacturing scale‑up, or strategic investments and may force external financing at unfavorable terms.

Earnings DeclineA large negative EPS growth rate reflects meaningful earnings pressure year‑over‑year, reducing the margin for error on future investments. Persisting EPS declines can limit retained earnings, weaken confidence in profitability trends, and complicate long‑term planning for R&D and commercialization.

Moderate Return On EquityAn ROE in the mid‑teens is respectable but modest for a growth‑oriented biotech; it suggests room to improve capital efficiency. If ROE does not rise with revenue scaling, shareholder value creation may lag industry peers, limiting long‑term upside from operational leverage.

StemCell Institute News

StemCell Institute Expands into Southeast Asia with Joint Venture

The latest announcement is out from StemCell Institute ( ($JP:7096) ). StemCell Institute Inc. has entered a joint...

7M ago

7096

7096 FAQ

What was StemCell Institute’s price range in the past 12 months?

StemCell Institute lowest stock price was ¥744.00 and its highest was ¥1462.00 in the past 12 months.

What is StemCell Institute’s market cap?

StemCell Institute’s market cap is ¥8.82B.

When is StemCell Institute’s upcoming earnings report date?

StemCell Institute’s upcoming earnings report date is May 07, 2026 which is in 76 days.

How were StemCell Institute’s earnings last quarter?

StemCell Institute released its earnings results on Feb 12, 2026. The company reported ¥6.12 earnings per share for the quarter, beating the consensus estimate of N/A by ¥6.12.

Is StemCell Institute overvalued?

According to Wall Street analysts StemCell Institute’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does StemCell Institute pay dividends?

StemCell Institute pays a Notavailable dividend of ¥25 which represents an annual dividend yield of N/A. See more information on StemCell Institute dividends here

What is StemCell Institute’s EPS estimate?

StemCell Institute’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does StemCell Institute have?

StemCell Institute has 10,246,600 shares outstanding.

What happened to StemCell Institute’s price movement after its last earnings report?

StemCell Institute reported an EPS of ¥6.12 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.296%.

Which hedge fund is a major shareholder of StemCell Institute?

Currently, no hedge funds are holding shares in JP:7096

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

StemCell Institute

StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is also involved in research and development of medical treatments using stem cells, as well as engages in banking of blood vessel cells businesses. StemCell Institute Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan. StemCell Institute Inc. is a subsidiary of Trim Medical Holdings Inc.